Literature DB >> 10563708

Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.

S D Lawn1, R J Shattock, J W Acheampong, R B Lal, T M Folks, G E Griffin, S T Butera.   

Abstract

OBJECTIVE: To determine the impact of treatment of tuberculosis on plasma HIV-1 load in African subjects and to correlate viral load with response to treatment and changes in immune activation.
DESIGN: Clinical and microbiological responses, immune activation parameters and plasma HIV-1 load were determined in 20 patients with pulmonary tuberculosis and HIV-1 coinfection in Ghana, West Africa during the first 3 months of anti-tuberculosis treatment.
METHODS: Plasma HIV-1 load and markers of immune activation were determined by commercially available assays. Human leukocyte antigen (HLA)-DR incorporation into the HIV-1 envelope was measured by using an immunomagnetic capture technique.
RESULTS: Treatment of tuberculosis resulted in significant improvements in weight and haemoglobin, a high sputum smear conversion rate and marked reductions in mean plasma tumour necrosis factor (TNF) receptor-1, interleukin-6 and C-reactive protein. Furthermore, incorporation of host HLA-DR into the HIV-1 envelope decreased; this also suggested a reduction in immune activation of the cells supporting viral replication. However, of importance with regard to AIDS pathogenesis, neither mean plasma TNF-alpha nor HIV-1 load decreased significantly.
CONCLUSIONS: The failure of HIV-1 plasma load to decline significantly during the initial months of anti-tuberculosis treatment is associated with high, sustained systemic levels of TNF-alpha. The dissociation between the sustained levels of plasma TNF-alpha and the major reductions in other, diverse immune activation parameters may represent dysregulation of cytokine production in these African patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563708     DOI: 10.1097/00002030-199911120-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

Review 1.  Antituberculosis treatment: increasing evidence for drug effects on innate cellular immunity.

Authors:  C T Tiemessen; S Shalekoff; S Meddows-Taylor; D J Martin
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection.

Authors:  S D Lawn; S T Butera
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Predictors of change in nutritional and hemoglobin status among adults treated for tuberculosis in Tanzania.

Authors:  K Kawai; E Villamor; F M Mugusi; E Saathoff; W Urassa; R J Bosch; D Spiegelman; W W Fawzi
Journal:  Int J Tuberc Lung Dis       Date:  2011-10       Impact factor: 2.373

4.  Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients.

Authors:  Z Toossi; H Mayanja-Kizza; C S Hirsch; K L Edmonds; T Spahlinger; D L Hom; H Aung; P Mugyenyi; J J Ellner; C W Whalen
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 5.  Effect of treating co-infections on HIV-1 viral load: a systematic review.

Authors:  Kayvon Modjarrad; Sten H Vermund
Journal:  Lancet Infect Dis       Date:  2010-07       Impact factor: 25.071

6.  Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.

Authors:  S D Lawn; M O Labeta; M Arias; J W Acheampong; G E Griffin
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

7.  Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.

Authors:  C Scott Mahan; Maria Walusimbi; Denise F Johnson; Christina Lancioni; Edwin Charlebois; Joyce Baseke; Keith A Chervenak; Roy D Mugerwa; Diane V Havlir; Harriet Mayanja-Kizza; Christopher C Whalen; W Henry Boom
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

Review 8.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Humoral response against Cryptococcus neoformans mannoprotein antigens in HIV-infected patients.

Authors:  L Pitzurra; S Perito; F Baldelli; F Bistoni; A Vecchiarelli
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

10.  Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa.

Authors:  Michael Schomaker; Matthias Egger; Mhairi Maskew; Daniela Garone; Hans Prozesky; Christopher J Hoffmann; Andrew Boulle; Lukas Fenner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.